Travers Smith LLP has advised Peel Hunt and WG Partners, in their capacity as joint bookrunners, on the £80m placing by Oxford Biomedica.
Oxford Biomedica is a leading gene and cell therapy company focused on developing life changing treatment for serious diseases.
Alongside the placing, Oxford Biomedica has agreed with Homology Medicines Inc. a $175m strategic acquisition of newly formed US-based manufacturing business, Oxford Biomedica Solutions LLC.
The Travers Smith team was led by Corporate Director Neal Watson, supported by Senior Associate Joe Knox. US Securities law advice was provided by Senior Counsel Brent Sanders.
Oxford Biomedica was advised by Corporate Partner Paul Claydon and Senior Associate Trudy Dargeviciute at Covington & Burling LLP.
